These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27045472)

  • 1. Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis.
    Cordani M; Pacchiana R; Butera G; D'Orazi G; Scarpa A; Donadelli M
    Cancer Lett; 2016 Jul; 376(2):303-9. PubMed ID: 27045472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53's Extended Reach: The Mutant p53 Secretome.
    Pavlakis E; Stiewe T
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32075247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autocrine mechanisms of cancer chemoresistance.
    Butera G; Pacchiana R; Donadelli M
    Semin Cell Dev Biol; 2018 Jun; 78():3-12. PubMed ID: 28751251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression.
    Cathcart JM; Banach A; Liu A; Chen J; Goligorsky M; Cao J
    Oncotarget; 2016 Sep; 7(38):61107-61120. PubMed ID: 27531896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular Vesicles: Messengers of p53 in Tumor-Stroma Communication and Cancer Metastasis.
    Pavlakis E; Neumann M; Stiewe T
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.
    Neilsen PM; Noll JE; Suetani RJ; Schulz RB; Al-Ejeh F; Evdokiou A; Lane DP; Callen DF
    Oncotarget; 2011 Dec; 2(12):1203-17. PubMed ID: 22203497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of tumor microenvironment in collective tumor cell invasion.
    Wu JS; Sheng SR; Liang XH; Tang YL
    Future Oncol; 2017 May; 13(11):991-1002. PubMed ID: 28075171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential oncogenic roles of mutant-p53-derived exosomes in the tumor-host interaction of head and neck cancers.
    Azulay EE; Cooks T; Elkabets M
    Cancer Immunol Immunother; 2020 Feb; 69(2):285-292. PubMed ID: 31897662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.
    D'Orazi G; Cordani M; Cirone M
    Cell Mol Life Sci; 2021 Mar; 78(5):1853-1860. PubMed ID: 33070220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis.
    Brown GT; Murray GI
    J Pathol; 2015 Nov; 237(3):273-81. PubMed ID: 26174849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.
    Shakya R; Tarulli GA; Sheng L; Lokman NA; Ricciardelli C; Pishas KI; Selinger CI; Kohonen-Corish MRJ; Cooper WA; Turner AG; Neilsen PM; Callen DF
    Oncogene; 2017 Aug; 36(31):4469-4480. PubMed ID: 28368395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
    Neilsen PM; Noll JE; Mattiske S; Bracken CP; Gregory PA; Schulz RB; Lim SP; Kumar R; Suetani RJ; Goodall GJ; Callen DF
    Oncogene; 2013 Jun; 32(24):2992-3000. PubMed ID: 22797073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation.
    Servais C; Erez N
    J Pathol; 2013 Jan; 229(2):198-207. PubMed ID: 22996812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 regulates cytoskeleton remodeling to suppress tumor progression.
    Araki K; Ebata T; Guo AK; Tobiume K; Wolf SJ; Kawauchi K
    Cell Mol Life Sci; 2015 Nov; 72(21):4077-94. PubMed ID: 26206378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment: The culprit for ovarian cancer metastasis?
    Luo Z; Wang Q; Lau WB; Lau B; Xu L; Zhao L; Yang H; Feng M; Xuan Y; Yang Y; Lei L; Wang C; Yi T; Zhao X; Wei Y; Zhou S
    Cancer Lett; 2016 Jul; 377(2):174-82. PubMed ID: 27131957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mutant p53 in human cancer.
    Goh AM; Coffill CR; Lane DP
    J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
    Roger L; Jullien L; Gire V; Roux P
    J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
    Ali A; Shah AS; Ahmad A
    Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular interplay between mutant p53 proteins and autophagy in cancer cells.
    Cordani M; Butera G; Pacchiana R; Donadelli M
    Biochim Biophys Acta Rev Cancer; 2017 Jan; 1867(1):19-28. PubMed ID: 27871965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.